Jonathan M. Stokes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonathan M. Stokes has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Autumn Arnold
Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute of Infectious Disease Research, David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, Canada
7 shared publicationsJeremie Alexander
Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, Canada
5 shared publicationsStewart McLellan
Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute of Infectious Disease Research, David Braley Centre for Antibiotic Discovery, McMaster University, Hamilton, Canada
5 shared publications- Denise B. Catacutan
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
4 shared publications - Eric D. Brown
McMaster University
4 shared publications Gary Liu
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
4 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (6) , 833-867
SyntheMol-RL: a flexible reinforcement learning framework for designing easily synthesizable antibiotics
The rise of antibiotic-resistant pathogens such as Staphylococcus aureus has created an urgent need for new antibiotics. Generative artificial intelligence (AI) has shown promise in drug discovery, but existing models often fail to propose compounds that are both effective and synthetically tractable. To address these challenges, we introduce SyntheMol-RL, a reinforcement learning-based generative model that can rapidly design synthetically accessible small-molecule drug candidates from a massive chemical space of 46 billion compounds. SyntheMol-RL improves upon our prior Monte Carlo tree search (MCTS)-based SyntheMol model by generalizing across chemically similar building blocks and enabling multi-parameter optimization. We applied SyntheMol-RL to generate candidate antibiotics against S. aureus by optimizing for both antibacterial activity and aqueous solubility, and we found that SyntheMol-RL generated molecules with improved predicted properties compared to both the previous MCTS version of SyntheMol as well as an AI-based virtual screening baseline. We synthesized 79 SyntheMol-RL compounds that were unique relative to the training dataset and found that 13 showed potent in vitro activity, of which seven passed our structural novelty filters that compared them to known antibiotics. Furthermore, one hit compound, synthecin, demonstrated efficacy in a murine wound infection model of methicillin-resistant S. aureus (MRSA). These results validate SyntheMol-RL’s ability to generate synthetically accessible candidate antibiotics and position SyntheMol-RL as a powerful tool for drug design across therapeutic domains.
- 23 April 2026
- Published by Springer Nature in Molecular Systems Biology
- Vol. 22 (6) , 833-867
Open AccessSyntheMol-RL: a flexible reinforcement learning framework for designing easily synthesizable antibiotics
The rise of antibiotic-resistant pathogens such as Staphylococcus aureus has created an urgent need for new antibiotics. Generative artificial intelligence (AI) has shown promise in drug discovery, but existing models often fail to propose compounds that are both effective and synthetically tractable. To address these challenges, we introduce SyntheMol-RL, a reinforcement learning-based generative model that can rapidly design synthetically accessible small-molecule drug candidates from a massive chemical space of 46 billion compounds. SyntheMol-RL improves upon our prior Monte Carlo tree search (MCTS)-based SyntheMol model by generalizing across chemically similar building blocks and enabling multi-parameter optimization. We applied SyntheMol-RL to generate candidate antibiotics against S. aureus by optimizing for both antibacterial activity and aqueous solubility, and we found that SyntheMol-RL generated molecules with improved predicted properties compared to both the previous MCTS version of SyntheMol as well as an AI-based virtual screening baseline. We synthesized 79 SyntheMol-RL compounds that were unique relative to the training dataset and found that 13 showed potent in vitro activity, of which seven passed our structural novelty filters that compared them to known antibiotics. Furthermore, one hit compound, synthecin, demonstrated efficacy in a murine wound infection model of methicillin-resistant S. aureus (MRSA). These results validate SyntheMol-RL’s ability to generate synthetically accessible candidate antibiotics and position SyntheMol-RL as a powerful tool for drug design across therapeutic domains.
- 18 December 2025
- Published by Springer Nature in Nature Computational Science
- Vol. 6 (1) , 13-14
AI-guided molecular design with recipes included
- 18 December 2025
- Published by Springer Nature in Nature Computational Science
- Vol. 6 (1) , 13-14
AI-guided molecular design with recipes included
- Open Access
- 24 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (12) , 3363
Author Correction: Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic
- 24 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (12) , 3363
Open AccessAuthor Correction: Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic
- 3 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 2808-2822
Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic
Current clinical antibiotics are largely broad-spectrum agents that can alter the gut microbiome and promote colonization by Enterobacteriaceae, which are often drug resistant. This includes adherent-invasive Escherichia coli (AIEC), particularly in patients with inflammatory bowel disease, in which dysbiosis creates a niche for this pathogen to colonize. There is an urgent and unmet need for novel narrow-spectrum and microbiome-sparing antibiotics. Here we screened 10,747 bioactive small molecules for antibacterial activity against AIEC and discovered enterololin, an antibacterial compound with targeted activity against Enterobacteriaceae species. Enterololin could overcome intrinsic and acquired resistance mechanisms in clinical isolates when combined with a subinhibitory concentration of SPR741, a polymyxin B analogue used here to increase outer membrane permeability in Gram-negative bacteria. Molecular substructure- and deep learning-guided mechanism-of-action investigations revealed that enterololin perturbs lipoprotein trafficking through a mechanism involving the LolCDE complex, laboratory-evolved resistant mutants predominantly mapped to lolC and lolE, with an in vitro frequency of resistance of ~10−8 to 10−7. Enterololin showed low mammalian cytotoxicity (HEK293 half-maximal inhibitory concentration ~100 µg ml−1) and suppressed AIEC infection in mouse models when administered in combination with SPR741, while largely preserving the overall microbiome composition. This study highlights the utility of deep learning methods for predicting molecular interactions and identifies a promising Enterobacteriaceae-specific antibacterial candidate for further development.
- 3 October 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (11) , 2808-2822
Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic
Current clinical antibiotics are largely broad-spectrum agents that can alter the gut microbiome and promote colonization by Enterobacteriaceae, which are often drug resistant. This includes adherent-invasive Escherichia coli (AIEC), particularly in patients with inflammatory bowel disease, in which dysbiosis creates a niche for this pathogen to colonize. There is an urgent and unmet need for novel narrow-spectrum and microbiome-sparing antibiotics. Here we screened 10,747 bioactive small molecules for antibacterial activity against AIEC and discovered enterololin, an antibacterial compound with targeted activity against Enterobacteriaceae species. Enterololin could overcome intrinsic and acquired resistance mechanisms in clinical isolates when combined with a subinhibitory concentration of SPR741, a polymyxin B analogue used here to increase outer membrane permeability in Gram-negative bacteria. Molecular substructure- and deep learning-guided mechanism-of-action investigations revealed that enterololin perturbs lipoprotein trafficking through a mechanism involving the LolCDE complex, laboratory-evolved resistant mutants predominantly mapped to lolC and lolE, with an in vitro frequency of resistance of ~10−8 to 10−7. Enterololin showed low mammalian cytotoxicity (HEK293 half-maximal inhibitory concentration ~100 µg ml−1) and suppressed AIEC infection in mouse models when administered in combination with SPR741, while largely preserving the overall microbiome composition. This study highlights the utility of deep learning methods for predicting molecular interactions and identifies a promising Enterobacteriaceae-specific antibacterial candidate for further development.
- 20 August 2025
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 7 (8) , 1192-1194
The importance of negative training data for robust antibody binding prediction
- 20 August 2025
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 7 (8) , 1192-1194
The importance of negative training data for robust antibody binding prediction
- Open Access
SyntheMol-RL: a flexible reinforcement learning framework for designing novel and synthesizable antibiotics
The rise of antibiotic-resistant pathogens such as Staphylococcus aureus has created an urgent need for new antibiotics. Generative artificial intelligence (AI) has shown promise in drug discovery, but existing models often fail to propose compounds that are both effective and synthetically tractable. To address these challenges, we introduce SyntheMol-RL, a reinforcement learning-based generative model that can rapidly design synthetically accessible small molecule drug candidates from a massive chemical space of 46 billion compounds. SyntheMol-RL improves upon our prior Monte Carlo Tree Search (MCTS)-based SyntheMol model by generalizing across chemically similar building blocks and enabling multi-parameter optimization. We applied SyntheMol-RL to generate candidate antibiotics against S. aureus by optimizing for both antibacterial activity and aqueous solubility, and we found that SyntheMol-RL generated molecules with improved predicted properties compared to both the previous MCTS version of SyntheMol as well as an AI-based virtual screening baseline. We synthesized 79 SyntheMol-RL compounds that were unique relative to the training dataset and found that 13 showed potent in vitro activity, of which seven were structurally novel after detailed literature searches. Furthermore, one hit compound, synthecin, demonstrated efficacy in a murine wound infection model of methicillin-resistant S. aureus (MRSA). These results validate SyntheMol-RL’s ability to generate novel and synthetically accessible candidate antibiotics and position SyntheMol-RL as a powerful tool for drug design across therapeutic domains.
Open AccessSyntheMol-RL: a flexible reinforcement learning framework for designing novel and synthesizable antibiotics
The rise of antibiotic-resistant pathogens such as Staphylococcus aureus has created an urgent need for new antibiotics. Generative artificial intelligence (AI) has shown promise in drug discovery, but existing models often fail to propose compounds that are both effective and synthetically tractable. To address these challenges, we introduce SyntheMol-RL, a reinforcement learning-based generative model that can rapidly design synthetically accessible small molecule drug candidates from a massive chemical space of 46 billion compounds. SyntheMol-RL improves upon our prior Monte Carlo Tree Search (MCTS)-based SyntheMol model by generalizing across chemically similar building blocks and enabling multi-parameter optimization. We applied SyntheMol-RL to generate candidate antibiotics against S. aureus by optimizing for both antibacterial activity and aqueous solubility, and we found that SyntheMol-RL generated molecules with improved predicted properties compared to both the previous MCTS version of SyntheMol as well as an AI-based virtual screening baseline. We synthesized 79 SyntheMol-RL compounds that were unique relative to the training dataset and found that 13 showed potent in vitro activity, of which seven were structurally novel after detailed literature searches. Furthermore, one hit compound, synthecin, demonstrated efficacy in a murine wound infection model of methicillin-resistant S. aureus (MRSA). These results validate SyntheMol-RL’s ability to generate novel and synthetically accessible candidate antibiotics and position SyntheMol-RL as a powerful tool for drug design across therapeutic domains.
- Top Cited PapersOpen Access
- 13 March 2025
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 3 (1) , 1-15
How AI can help us beat AMR
Antimicrobial resistance (AMR) is an urgent public health threat. Advancements in artificial intelligence (AI) and increases in computational power have resulted in the adoption of AI for biological tasks. This review explores the application of AI in bacterial infection diagnostics, AMR surveillance, and antibiotic discovery. We summarize contemporary AI models applied to each of these domains, important considerations when applying AI across diverse tasks, and current limitations in the field.
- 13 March 2025
- Published by Springer Nature in npj Antimicrobials and Resistance
- Vol. 3 (1) , 1-15
Top Cited PapersOpen AccessHow AI can help us beat AMR
Antimicrobial resistance (AMR) is an urgent public health threat. Advancements in artificial intelligence (AI) and increases in computational power have resulted in the adoption of AI for biological tasks. This review explores the application of AI in bacterial infection diagnostics, AMR surveillance, and antibiotic discovery. We summarize contemporary AI models applied to each of these domains, important considerations when applying AI across diverse tasks, and current limitations in the field.
- 24 January 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (2) , 267-269
Explainable artificial intelligence evolves antimicrobial peptides
- 24 January 2025
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (2) , 267-269
Explainable artificial intelligence evolves antimicrobial peptides
- Top Cited Papers
- 19 July 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (8) , 960-973
Machine learning in preclinical drug discovery
Drug-discovery and drug-development endeavors are laborious, costly and time consuming. These programs can take upward of 12 years and cost US $2.5 billion, with a failure rate of more than 90%. Machine learning (ML) presents an opportunity to improve the drug-discovery process. Indeed, with the growing abundance of public and private large-scale biological and chemical datasets, ML techniques are becoming well positioned as useful tools that can augment the traditional drug-development process. In this Perspective, we discuss the integration of algorithmic methods throughout the preclinical phases of drug discovery. Specifically, we highlight an array of ML-based efforts, across diverse disease areas, to accelerate initial hit discovery, mechanism-of-action (MOA) elucidation and chemical property optimization. With advances in the application of ML across diverse therapeutic areas, we posit that fully ML-integrated drug-discovery pipelines will define the future of drug-development programs.
- 19 July 2024
- Published by Springer Nature in Nature Chemical Biology
- Vol. 20 (8) , 960-973
Top Cited PapersMachine learning in preclinical drug discovery
Drug-discovery and drug-development endeavors are laborious, costly and time consuming. These programs can take upward of 12 years and cost US $2.5 billion, with a failure rate of more than 90%. Machine learning (ML) presents an opportunity to improve the drug-discovery process. Indeed, with the growing abundance of public and private large-scale biological and chemical datasets, ML techniques are becoming well positioned as useful tools that can augment the traditional drug-development process. In this Perspective, we discuss the integration of algorithmic methods throughout the preclinical phases of drug discovery. Specifically, we highlight an array of ML-based efforts, across diverse disease areas, to accelerate initial hit discovery, mechanism-of-action (MOA) elucidation and chemical property optimization. With advances in the application of ML across diverse therapeutic areas, we posit that fully ML-integrated drug-discovery pipelines will define the future of drug-development programs.
- Top Cited Papers
- 22 March 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (3) , 338-353
Generative AI for designing and validating easily synthesizable and structurally novel antibiotics
- 22 March 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (3) , 338-353
Top Cited PapersGenerative AI for designing and validating easily synthesizable and structurally novel antibiotics